Home » Pipeline
Pipeline
August 24, 2020
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Algernon Pharmaceuticals | NP-120 (Ifenprodil) | hospitalized patients with confirmed COVID-19 | first patient enrolled in the U.S. in phase 2b/3 trial |
| Enzychem LifeSciences | EC-18 | patients with acute respiratory distress syndrome (ARDS) due to COVID-19 pneumonia | IND approved by the FDA for phase 2 trial |
| Accelerate Diagnostics | BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully automated MS-Fast instrument | COVID-19 antibody test | Emergency Use Authorization (EUA) granted by the FDA |
| LumiraDx | LumiraDx SARS-CoV-2 antigen test | detection of SARS-CoV-2 antigens | EUA granted by the FDA |
| Other Trials and Actions | |||
| CARsgen Therapeutics | CT041 | claudin18.2-positive solid tumors | IND approved by the FDA |
| Acepodia | ACE1702 | HER2-expressing solid tumors | first patients dosed in phase 1 trial |
| Arrowhead Pharmaceuticals | ARO-HIF2 | clear-cell renal cell carcinoma | first patients dosed in phase 1b trial |
| Enterprise Therapeutics | ETD002 | all cystic fibrosis patients, independent of genotype | first patients dosed in phase 1 trial |
| Epirium Bio | EPM-01 | Becker muscular dystrophy | enrollment of first patients in phase 1 trial |
| Immunic | IMU-856 | diarrhea-predominant irritable bowel syndrome (IBS-D), ulcerative colitis (UC) and Crohn's disease | dosing of first patients in phase 1 trial |
| I-Mab | plonmarlimab (TJM2) | rheumatoid arthritis | dosing of first patient in phase 1b trial |
| Pluristem Therapeutics | PLX-R18 | incomplete hematopoietic recovery following hematopoietic cell transplantation | patient enrollment complete in phase 1 trial |
| Ultimovacs ASA | UV1 in combination with pembrolizumab | metastatic malignant melanoma | patient enrollment complete in phase 1 trial |
| 4D Molecular Therapeutics | 4D-125 | X-linked retinitis pigmentosa | initiation of phase 1/2 trial |
| Trefoil Therapeutics | TTHX1114 | regenerative treatment of corneal endothelial dystrophies | initiation of phase 1/2 trial |
| Alkermes | ALKS 4230 | advanced, malignant solid tumors | initiation of phase 2 trial |
| Amplyx | MAU868 | BK viremia in kidney transplant recipients | dosing of first patient in phase 2 trial |
| Ascletis Pharma | ASC22 (Envafolimab) | chronic hepatitis B | dosing of first patient in phase 2a trial |
| AzurRx | MS1819 | cystic fibrosis patients with exocrine pancreatic insufficiency | dosing of first patients in phase 2b trial |
| Imara | IMR-687 | adult patients with sickle cell disease | dosing of first patient in phase 2b trial |
| Neuroptika | NRO-1 | dry eye disease | patient enrollment complete in phase 2 trial |
| Verona Pharma | pressurized metered-dose inhaler (pMDI) formulation of ensifentrine | moderate to severe chronic obstructive pulmonary disease | initiation of phase 2 trial |
| BioLineRx | motixafortide (BL-8040) | mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma | patient enrollment complete in phase 2 trial |
| Endospan | NEXUS Aortic Arch Stent Graft System | thoracic aortic arch disease | IDE approved by the FDA |
| 4D Molecular Therapeutics | 4D-310 | Fabry Disease | Fast Track designation granted by the FDA |
| Akeso Biopharma | AK104 | patients with recurrent or metastatic squamous cervical cancer who have disease progression on or after platinum-based chemotherapy | Fast Track designation granted by the FDA |
| Precision Biosciences | PBCAR0191 | advanced B-cell precursor acute lymphoblastic leukemia | Fast Track designation granted by the FDA |
| Mustang Bio | MB-107 | X-linked severe combined immunodeficiency in newly diagnosed infants | Rare Pediatric Disease designation granted by the FDA |
| Scholar Rock | SRK-015 | spinal muscular atrophy | Rare Pediatric Disease designation granted by the FDA |
| Genentech | Enspryng (satralizumab-mwge) | adults with AQP4 antibody-positive neuromyelitis optica spectrum disorder | approved by the FDA |
| RapidAI | Rapid LVO | detecting suspected large vessel occlusions | approved by the FDA |
